Article Text

Download PDFPDF
A patient’s wish: anakinra in pregnancy
  1. C T Berger1,
  2. M Recher1,
  3. U Steiner1,
  4. T M Hauser1,2
  1. 1
    Immunology Clinic, Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland
  2. 2
    Immunologie-Zentrum Zürich, Zurich, Switzerland
  1. Correspondence to Dr T Hauser, Immunologie-Zentrum Zürich, Walchestrasse 11, 8006 Zurich, Switzerland; hauser{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Patients with adult-onset Still’s disease (AOSD) are at increased risk for adverse outcomes of pregnancy. An increased rate of preterm birth, intrauterine growth retardation and a possible influence of disease activity on pregnancy outcome have been reported.1 Interleukin 1 (IL1) is thought to have a key role in the pathogenesis of AOSD. Interestingly, it has also been related to an increased risk of preterm birth in animal models.2 3 An increasing number of reports on treatment of refractory AOSD with IL1 receptor antagonist (anakinra) emphasise its dramatic therapeutic effect and the rarity of its adverse events.4 5 However, its effects in pregnancy are not well known. Here we report successful continuous treatment of AOSD during pregnancy and breastfeeding.

A 33-year-old woman with …

View Full Text


  • Funding Funded by University Hospital Zurich, 8091 Zurich, Switzerland.

  • Competing interests None.

  • MR and US contributed equally.

  • Provenance and peer review Not commissioned; externally peer reviewed.